// App-Quantinova.ai

648 : Neoadjuvant chemotherapy with nonpegylated liposome-encapsulated doxorubicin (NPLD) plus cyclophosphamide followed by trastuzumab plus nabpaclitaxel for HER2-positive breast cancer (BC).

Researchers

Presenter

  • Silvana Saracchini

Principal Investigators

  • Luisa Foltran

  • Anna Bassini

  • Elvia Micheli

  • Alessandro Favero

  • Wally Marus

  • Alessandro Del Conte

  • Giuseppina Gusso

  • Stefania Manente

  • Salvatore Tumolo

  • Sandro Sulfaro

  • Michele Lorenzon

Medical Centers

  • Surgery Department, Hospital, Pordenone, Italy

  • Santa Maria degli Angeli Hospital, Pordenone, ItalyDepartment of Oncology, General Hospital, Pordenone, ItalySanta Maria degli Angeli GH, Pordenone, Italy

  • Medical Oncology Unit, St Maria degli Angeli Hospital, Pordenone, Italy

  • Surgery Department, Hospital, Pordenone, Italy

  • Pordenone, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Neutropenia

  • Solid malignancies

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Doxorubicin Hydrochloride

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Trastuzumab

  • Doxorubicin

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved